https://www.asiabiotech.com/22/2206/22060024x.html

Breast cancer is the top cancer affecting women worldwide. In Singapore, it is estimated that 1 in 14 women will develop breast cancer before the age of 75 and its incidence continues to rise.

The treatment may involve various modalities, including surgery, chemotherapy, radiotherapy, immunotherapy, hormonal therapy etc. Treatment recommendations for breast cancer vary according to the extent of disease and the subtype of the tumour (hormone receptor-positive, HER2-positive, triple-negative).

Therefore, the treatment of breast cancer requires a multidisciplinary approach but it was only after 1970s when the first multidisciplinary breast centre was established in the United States. Since then, it became evident that better patients’ outcomes were achieved when various medical specialists worked as a team. While multidisciplinary team-based approach is adopted in Singapore for breast cancer care, this ideal approach is not widely adopted in other Asia-Pacific countries.

Click the link https://www.asiabiotech.com/22/2206/22060024x.html for an article featured on Asia Pacific Biotech News (APBN) Vol 22, No 06, June 2018 and read on to find out the roles of the various medical specialists working together as a team to battle breast cancer, and understand why the approach is yet widely available in less medically advanced countries. The article is contributed by our Dr Tan Sing Huang, Senior Consultant Medical Oncologist of ONCOCARE CANCER CENTRE (Singapore), and a team of other doctors from public and private institutions in Singapore.

Asia Pacific Biotech News (APBN) was first established in year 1997.

For 20 years, APBN has been providing comprehensive news in the areas of biotechnology, food, healthcare, pharmaceutical and life sciences in the Asia Pacific region.

APBN (print and online) is widely read by industry professionals, research.